Optimi Health Plans To Initiate Multisite Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy For Individuals With Major Depressive Disorder In H1 2027, With Dosing Expected To Be Complete By 2027 End
Health Canada-authorized trial to evaluate a single supervised dose of natural psilocybin, with dosing expected to be completed by the end of 2027Up to 200 participants at sites across Canada, among the largest studies
Optimi Health got approval to start a bigger test of psilocybin, a special medicine, to help people with serious sadness. This is an early stage test, so we watch to see if the medicine works and if the company can finish on time.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.